Evidence map›Paper›PMID 40114223›Full record

ArticleClinical epigenetics2025

DNA methylation heterogeneity correlates with field cancerization and prognosis in lung adenocarcinoma patients.

Ying Zhou, Jing Zhang, Yang He, Yun Wang, Bing Li, Tengfei Zhu, Yanjun Su

Abstract read
In one paragraph

Article in Clinical epigenetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ying ZhouDepartment of Integrative Oncology, Tianjin Cancer Hospital Airport Hospital, Tianjin, China.
Jing ZhangDepartment of Integrative Oncology, Tianjin Cancer Hospital Airport Hospital, Tianjin, China.
Yang HeDepartment of Breast Cancer, Tianjin Cancer Hospital Airport Hospital, Tianjin, China.
Yun WangDepartment of Integrative Oncology, Tianjin Cancer Hospital Airport Hospital, Tianjin, China.
Bing LiBurning Rock Biotech, Guangzhou, China.
Tengfei ZhuBurning Rock Biotech, Guangzhou, China.
Yanjun SuDepartment of Thoracic Oncology, Tianjin Cancer Hospital Airport Hospital, No.99 Dongwudao Road, Tianjin, 300308, China. yanjunsu@yeah.net.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLung adenocarcinoma (LUAD) is the most common histological subtype of lung cancer. The distinctive genetic and epigenetic modifications in tumors and paired non-malignant samples, such as adjacent peri-tumor and tumor-distant normal lung tissues, have not been adequately studied.

methodsWe recruited 57 patients with resectable stage I-III LUAD and collected matched samples of the primary tumor, peri-tumoral tissues, and tumor-distant normal lung tissue. We performed bisulfite sequencing using a custom methylation panel to profile DNA methylation levels and obtained somatic variation landscape through targeted next-generation sequencing (NGS). We attempted to identify differential methylation blocks (DMBs) between the tumor, peri-tumor, and normal tissues.

resultsWe analyzed the DNA methylation patterns of matched tumor, peri-tumor, and normal lung tissue samples from 57 LUAD patients. No significantly different methylation blocks were found between peri-tumoral and normal tissues, while they both exhibited distinct methylation profiles compared to tumor tissues. A total of 1329 tumor-specific DMBs, which are potentially associated with aberrant gene expression in LUAD, were identified. Utilizing a consensus clustering algorithm, we classified the tumor samples into two subgroups (C1 and C2) based on distinct methylation profiles, independent of the patient's sex, tumor stage, smoking history, and tumor cell fraction. The C2 subgroup exhibited a higher malignancy density ratio (MD ratio), suggesting a more pronounced degree of field cancerization, while the C1 subgroup was characterized by a higher frequency of EGFR mutations. The DMBs between the two subgroups were enriched in the calcium signaling pathway. Notably, P2RX2 shows significant hypermethylation in the C2 subgroup, and its low expression in the external The Cancer Genome Atlas (TCGA) cohort may correlate with reduced overall survival in LUAD patients.

conclusionOur findings revealed distinct methylation patterns between tumor and pre-malignant samples, such as peri-tumor and normal tissues. Moreover, our study suggests that distinct clustering based on DNA methylation may indicate different prognoses in LUAD patients.

Indexed as

Adenocarcinoma of LungDNA MethylationLung NeoplasmsAgedEpigenesis, GeneticFemaleGene Expression Regulation, NeoplasticGenetic HeterogeneityHigh-Throughput Nucleotide SequencingHumansMaleMiddle AgedPrognosisCalcium signalingDNA methylationField cancerizationLung adenocarcinomaP2RX2

Identifiers

PMID40114223
PMCPMC11924610

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.